sterna biologicals reports phase 2a study data demonstrating efficacy of its gata 3 specific dnazyme formulation sb012 in patients with ulcerative colitis

Marburg, Germany, February 19, 2018

  • Data presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).
  • SB012 was safe and well tolerated and led to marked clinical and endoscopic improvement in patients with active ulcerative colitis. This represents a further validation of GATA-3-antagonism for the treatment of a variety of chronic inflammatory diseases.

sterna biologicals GmbH & Co. KG ("sterna"), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced that positive data from the SECURE study (NCT 02129439), a Phase 2a trial in patients with moderate to severe ulcerative colitis treated with its GATA-3 specific DNAzyme formulation SB012, were presented at the 13th Congress of ECCO (European Crohn's and Colitis Organisation).

sterna biologicals to participate in upcoming international conferences in H1 2018

Marburg, Germany, 01 February 2018
sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announces its participation in the following key scientific and partnering conferences in the first half of 2018:

13th Congress of ECCO - European Crohn's and Colitis Organisation
Date: February 14-17, 2018 in Vienna, Austria

German Center for Lung Research (DZL) successfully completes investigator-initiated study evaluating SB010 in COPD patients

Marburg, Germany, 11 September 2017

  • Results presented today at the European Respiratory Society International Congress 2017 in Milan, Italy

sterna biologicals GmbH & Co. KG ("sterna biologicals") announced today that investigator Dr Timm Greulich from the Department of Medicine, Pulmonary and Critical Care Medicine, Philipps University Marburg, will present key results of the recently completed Phase II clinical trial of SB010 at the European Respiratory Society (ERS) Congress held in Milan, Italy, 9 to 13 September 2017.

sterna biologicals appoints Christian Pangratz as Chief Executive Officer

Marburg, Germany, 8 January 2018

sterna biologicals GmbH & Co. KG (Sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, announced today that the Company has appointed Christian M. Pangratz as Chief Executive Officer. He brings over 25 years of life sciences experience, notably in the areas of strategic planning, corporate and business development, alliance and project management, new product planning, marketing and sales.

sterna biologicals co-founders receive Paul Martini Prize

Marburg, Germany, 01 May 2017
sterna biologicals GmbH & Co. KG ("sterna biologicals") is pleased to announce that two of its co-founders, Prof. Dr. Holger Garn and Prof. Dr. Harald Renz, were selected to receive this year's Paul Martini Prize. The prize is one of the most prestigious prizes in the field of medicine in Germany and is awarded by the Paul Martini Foundation for exceptional research achievements in the development of novel clinically relevant therapeutic approaches. The prize will be awarded today on the occasion of the 123rd Congress of the German Society for Internal Medicine in Mannheim.